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Abstract
Background: The Global Burden of Disease Study 2010 (GBD 2010) identified mental and substance use disorders as the 5th
leading contributor of burden in 2010, measured by disability adjusted life years (DALYs). This estimate was incomplete as it
excluded burden resulting from the increased risk of suicide captured elsewhere in GBD 2010’s mutually exclusive list of
diseases and injuries. Here, we estimate suicide DALYs attributable to mental and substance use disorders.
Methods: Relative-risk estimates of suicide due to mental and substance use disorders and the global prevalence of each
disorder were used to estimate population attributable fractions. These were adjusted for global differences in the
proportion of suicide due to mental and substance use disorders compared to other causes then multiplied by suicide
DALYs reported in GBD 2010 to estimate attributable DALYs (with 95% uncertainty).
Results: Mental and substance use disorders were responsible for 22.5 million (14.8–29.8 million) of the 36.2 million (26.5–
44.3 million) DALYs allocated to suicide in 2010. Depression was responsible for the largest proportion of suicide DALYs
(46.1% (28.0%–60.8%)) and anorexia nervosa the lowest (0.2% (0.02%–0.5%)). DALYs occurred throughout the lifespan, with
the largest proportion found in Eastern Europe and Asia, and males aged 20–30 years. The inclusion of attributable suicide
DALYs would have increased the overall burden of mental and substance use disorders (assigned to them in GBD 2010 as a
direct cause) from 7.4% (6.2%–8.6%) to 8.3% (7.1%–9.6%) of global DALYs, and would have changed the global ranking from
5th to 3rd leading cause of burden.
Conclusions: Capturing the suicide burden attributable to mental and substance use disorders allows for more accurate
estimates of burden. More consideration needs to be given to interventions targeted to populations with, or at risk for,
mental and substance use disorders as an effective strategy for suicide prevention.
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Introduction
There has been growing recognition of the importance of
mental and substance use disorders as contributors to health loss in
all countries. The Global Burden of Disease Study 2010 (GBD
2010) is the largest and most recent effort to quantify this by
systematically integrating years of life lost (YLLs) and years of life
with disability (YLDs) into disability adjusted life years (DALYs)
for diseases, injuries and risk factors [1–7].
GBD 2010 presented age-, sex-, year-, country-, and region-
specific DALYs for 291 diseases and injuries as well as for 67 risk
factors [1–7]; using improved methodology compared to previous
GBD studies [8,9]. Mental and substance use disorders explained
7.4% (95% uncertainty interval: 6.2–8.6%) of total DALYs in
2010, confirming them as the leading disease category of YLDs,
and the 5th leading category of DALYs globally [10–12]. This
estimate reflects ‘direct burden’ where mental and substance use
disorders are the direct cause of health loss, but excludes the excess
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(attributable) burden resulting from the increased risk of mortality
and disability due to subsequent health outcomes captured
elsewhere in the mutually exclusive disease and injury categories
in GBD 2010. Jointly considering the direct and the attributable
burden of mental and substance use disorders provides an
estimation of the putative causal relationship between the
disorders and other health outcomes. This is of clinical and policy
relevance as it clearly delineates the disability and mortality that
potentially can be modified by interventions to prevent and treat
mental and substance use disorders.
Here, we expand on the published GBD 2010 findings by
estimating the additional burden attributable to mental and
substance use disorders as risk factors for suicide. Suicide, defined
as deaths caused by intentional, self-inflicted poisoning or injury
[13], was the 13th leading cause of YLLs worldwide in 2010 [1,6].
Nearly 1 million people complete suicide every year with over
50% aged between 15 and 44 years [14,15]. Over 80% of suicides
occur in low to middle income countries and close to 50% occur in
India and China alone [15,16]. Suicide from firearms, car exhaust
and poisoning are more common in high income countries and
suicide from pesticide poisoning, hanging and self-immolation are
more common in low to middle income countries [17]. It is
important to consider these differences in the global epidemiology
of suicide while quantifying the suicide burden attributable to
mental and substance use disorders.
The link between mental and substance use disorders and
suicide is well documented [14–20] and authors such as Prince and
colleagues argued [14] that failure to include suicide as part of
mental and substance use disorder estimates in the previous GBD
studies [8,9] led to an underestimate of the extent of the burden. A
literature review and meta-analysis by Harris and Barraclough
showed that of the 249 studies and 44 mental disorders assessed,
36 disorders were associated with an increased risk of suicide [19].
Li and collaborators also found that the risk of suicide was 7.5
(6.2–9.0) times higher in males and 11.7 (9.7–14.1) times higher in
females with a mental or substance use disorder compared to
males and females with no disorder. Depression and bipolar
disorder accounted for the highest risk [20]. Even when other risk
factors such as adverse marital effects, employment and socio-
economic status were considered, mental and substance use
disorders remain strongly associated with suicide [20,21].
Quantifying the suicide burden attributable to mental and
substance use disorders also corrects for the low burden from
premature mortality (YLLs) directly attributed to mental and
substance use disorders in GBD 2010. Although mental and
substance use disorders were identified as a leading cause of global
burden, YLDs contributed to 95% of DALYs [5,10]. In spite of
evidence of excess mortality attributable to many mental and
substance use disorders, only substance use disorders, anorexia
nervosa, and schizophrenia are recognized as underlying causes of
death in the International Classification of Diseases (ICD-10)
cause of death guidelines [13] used in GBD 2010. Even for those
disorders, few deaths were captured in the vital registrations used
in the estimation of YLLs, as this typically involves the
cumbersome task of disentangling the effect of multiple mental,
substance and physical disorders to identify primary cause of
death.
Investigating mental and substance use disorders as risk factors
for fatal outcomes like suicide allows us to circumvent this problem
by making use of GBD 2010’s comparative risk analysis (CRA)
methodology [7]. Rather than rely on certification and coding
practices in mortality registration systems, this method allows
quantification of the difference in population health in a
counterfactual with a theoretical minimum level of exposure [7].
We make use of this method here to calculate the suicide burden
attributable to mental and substance use disorders, and examine
variations by region, country, age, year and disorder.
Methods
The suicide burden attributable to mental and substance use
disorders was estimated by comparing the current health status
with a theoretical-minimum-risk exposure defined as the counter-
factual status of the absence of mental and substance use disorders.
Population attributable fractions (PAFs) were determined from the
prevalence of exposure to each disorder and the relative-risk (RR)
of suicide [7]. For each disorder this involved:
1. Reviewing the strength of the evidence for a causal relationship
between the disorder and suicide.
2. Expanding on existing systematic reviews of the literature
quantifying the effect size for the disorder as a risk factor for
suicide. The preferred metric was population-representative
RR estimates.
3. Pooling all RR estimates using meta-analysis.
4. Combining the pooled RR estimate with GBD 2010
prevalence estimates to generate PAFs by age, sex, country,
and year.
5. Adjusting PAFs for global differences in suicide attributable to
mental and substance use disorders versus differences attribut-
able to other causes.
6. Multiplying PAFs by suicide YLLs reported in GBD 2010 to
estimate attributable burden.
Case definition
GBD methods suggest that for each risk factor-outcome pairing,
there should be (1) sufficient data to enable estimation of relative
effect sizes as well as (2) sufficient evidence for a causal effect [7]. A
literature review by Baxter and collaborators [22] as well as other
studies summarised in the previous section [14–20] investigating
mental and substance use disorders as risk factors for other health
outcomes found sufficient evidence to meet these two conditions
for suicide.
Mental and substance use disorders investigated were those
included in GBD 2010 for which there was evidence of an
increased risk of suicide [10,19,20]. These were major depressive
disorder (MDD), bipolar disorder, schizophrenia, anxiety disorder,
anorexia nervosa, alcohol dependence, amphetamine dependence,
cocaine dependence and opioid dependence. All disorders were
defined using the Diagnostic and Statistical Manual of Mental
disorders (DSM) [23] or ICD diagnostic criteria [13]. Suicide was
defined as cases meeting ICD-10 cause of death codes for
intentional self-inflicted poisoning or injury (X60–X84) [13]. In
some countries a large proportion of injury-related deaths are
coded as ‘underdetermined intent’ for cultural, religious or
medico-legal reasons. GBD 2010 developed a method to
redistribute these deaths to specific underlying causes, including
suicide [6]. Although GBD 2010 also considered the effects of
attempted suicide as ‘non-fatal self-harm’ [5], this was not
investigated in this paper.
Literature search to identify relative-risk estimates
We used data sources from recent and methodologically
comparable systematic reviews of the association between suicide
and mental and substance use disorders [20,24–27], specifically
affective disorders, anxiety disorders, schizophrenia (14 studies
from these 3 disorder groups) [20], cocaine, opioid, and
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amphetamine dependence (24 studies) [24–26] and alcohol
dependence (12 studies) [27]. We expanded the Li and collabo-
rators systematic review and replicated the literature search [20] to
collect data for bipolar disorder and MDD separately (rather than
affective disorders combined), and anorexia nervosa which was not
included in the original review. The search strategy used was in
keeping with the Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) statement [28] (See Text
S1 in File S1 for the PRISMA checklist and flow diagram).
Electronic databases (Medline and Embase) were searched
between 1966 and 2010. A secondary search of reference lists
and the grey literature was also conducted. Studies were included
that; (1) considered mental and substance use disorders as a risk
factor associated with suicide; (2) reported a RR with 95%
uncertainty, or provided sufficient information for these to be
calculated; (3) were individual-level case-control or cohort studies
where a clear temporal association between exposure and outcome
could be determined; (4) had a minimum follow up period of 1
year and; (5) included disorders based on ICD [13] or DSM [23]
nomenclature to ensure consistency in case definitions. Sex-
specific data were preferred but non sex-specific estimates were
included (e.g. for substance use disorders) where data were sparse.
For each study, information on study methodology, quality and
findings were extracted into a Microsoft Excel spreadsheet. See
Table S1 in File S1 for a summary of the study variables extracted.
Meta-analysis of relative-risk estimates
For each disorder (except alcohol dependence for which a
pooled estimate was available [27]), MetaXL software, an add-in
for Microsoft Excel [29], was used to pool RR estimates from
different studies. This was done for males and females separately
and also combined. RR estimates were pooled using a random
effects model, and if there was sufficient data to do so, a quality
effects model [30]. Pooled RRs from the quality-effects model
were preferred as these gave greater weight to studies of high
quality versus studies of lesser quality, and avoided the anomaly of
random effects models which revert to equal weighting regardless
of sample size if heterogeneity is large [30–32]. Study quality was
assessed using a quality index which scored studies based on
sampling design and representativeness and also the availability of
age- and gender-specific estimates. It was limited to these items to
reduce potential subjectivity within and between quality scores. To
prevent inter-rater bias, all studies were rated by one researcher
and a random sample of scores was checked by an independent
researcher. See Table S1 in File S1 for the quality index and
scores.
Prevalence of mental and substance use disorders
We obtained the prevalence distribution of each mental and
substance use disorder from the epidemiological disease models
used in the calculation of direct burden (i.e. YLDs) in GBD 2010
[10,12]. These were based on a separate literature review
(presented in greater detail elsewhere [33–38]) conducted between
1980 to 2010 to capture studies reporting prevalence, incidence,
remission, duration and all cause-excess mortality associated with
mental and substance use disorders. Point (current or past month)
prevalence estimates of DSM/ICD defined disorders were
required. Twelve-month prevalence estimates were accepted to
maximize inclusion but adjusted towards the level of point
prevalence using study-level covariates. Lifetime prevalence was
excluded as it is more likely than point or period prevalence to be
affected by recall bias [39,40]. GBD 2010’s DisMod-MR, a
Bayesian meta-regression tool, was used to integrate these
estimates into an epidemiological disease model. From the
epidemiological inputs, DisMod-MR generated prevalence by
sex and age for 187 countries, 21 world regions and 1990, 2005
and 2010 [2,41]. Prevalent cases for each disorder have been
summarised in previous publications [2,10,12].
Population attributable fractions
PAFs were calculated from the DisMod-MR prevalence output
(P) for each disorder and the pooled RR of suicide given exposure
to the disorder. PAFs were calculated by age, sex, country, year
and disorder (consistent with the format of GBD 2010 estimates)
using the following formula [42]:
PAF~
p(RR{1)
p(RR{1)z1
Given the presence of comorbidity between mental and substance
use disorders, disorder-specific PAFs cannot be summed to obtain
the ‘joint effect’ of combined mental and substance use disorders
on suicide. Instead, a joint PAF was estimated using the
multiplicative method of adjusting for comorbidity between
disorders [43]. This can be understood as calculating the
complement of the product of the complements of each individual
PAF. The following formula was used where i is the individual risk
factor, and n is the total number of risk factors [7];
JointPAF~1{ P
n
i~1
(1{PAFi)
Ceiling values for joint population attributable fractions
Although studies from high income countries have consistently
shown that up to 90% of suicides occur as a result of an underlying
mental or substance use disorder [18,21,44], there is also evidence
to suggest that this proportion is substantially lower in China,
Taiwan and India; where symptoms of ‘dysphoric affect’ and
‘impulsivity’ (which do not constitute a mental and substance use
disorder) are expressed through more lethal methods of self-
harming such as pesticide poisoning and self-immolation [45–48].
This in turn, increases the number of completed suicides occurring
from self-harm behaviours (characteristically instigated as impul-
sive acts, without the presence of a mental and substance use
disorder or a clear intent to die) in these countries which would
have resulted in an ‘‘attempted suicide’’ had such methods not
been available [46,47].
So as not to overestimate the total proportion of suicide burden
attributable to mental and substance use disorders, we first
portioned out global differences in suicide attributable to mental
and substance use disorders from differences attributable to other
causes. More specifically, the total proportion of suicide cases
attributable to mental and substance use disorders in different
countries was calculated and used to set a ceiling value (or upper
threshold) for the joint PAFs. We examined reference lists of
existing reviews for psychological autopsy studies [18,21,44] and
conducted a supplementary literature search to capture additional
data sources up to 2010. The psychological autopsy method is a
retrospective assessment of causes of death which involves
canvassing the views of individuals closest to the deceased and
substantiating evidence from sources such as hospital and police
records [49]. The overall number of suicide cases attributable to
mental and substance use disorders was extracted from these
studies if DSM/ICD diagnostic criteria [13,23] were used and the
number of attributable suicide cases was reported for mental and
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substance use disorders as a group rather than for individual
disorders. If gender was not recorded we also accepted combined
estimates for males and females. Given that there were insufficient
data to calculate ceiling values individually for each country or
region, we pooled estimates into 2 broad categories based on the
percentage of suicide cases reported to be due to mental and
substance use disorders. Meta-analyses based on quality effects
models were used to generate separate pooled proportions for
Group 1: China, India and Taiwan and Group 2: all other
countries.
These calculated proportions of suicide cases due to mental and
substance use disorder were used to set the ceiling value of joint
PAFs. All quantities of interest in GBD 2010 were calculated a
thousand times in order to incorporate all sources of uncertainty.
Similarly, we created a thousand draws of the ‘ceiling values’ based
on the pooled estimates of mean and standard error. When
estimating the joint PAFs of suicide attributed to all mental and
substance use disorders we did not allow PAF estimates in any of
the one thousand draws to exceed the ceiling value in the
corresponding draw. For draws that did exceed the ceiling, we
scaled down each of the component mental and substance use
disorder PAFs by the ratio of the ceiling to the combined PAF.
Attributable burden
The final step was to multiply PAFs by the corresponding GBD
2010 YLLs for suicide [5,6] to calculate attributable burden. Since
only completed suicides were considered in our analyses, only
YLLs were included in attributable DALY estimates. To quantify
95% uncertainty around our final burden estimate we calculated
attributable YLLs and DALYs at the one thousand draw level and
bounded the 95% uncertainty interval by the 2.5 and 97.5 centile
values. All reporting of DALYs by region and country is based on
age-standardised estimates using direct standardization to the
global standard population proposed by the World Health
Organization (WHO) in 2001 [50].
Results
Pooled relative-risk estimates
Our search culminated in a dataset of 40 studies and 85 RR
estimates covering 14 countries (Table S1 in File S1 summarizes
included studies). There was a statistically significant increased risk
of suicide for all selected mental and substance use disorders
(table 1). The greatest risk was seen in MDD followed by
schizophrenia, and alcohol dependence. The 95% confidence
intervals around each pooled RR indicated high levels of
uncertainty with statistical heterogeneity (as measured by the I2
statistic) of up to 90%. A statistically significant sex difference was
only observed for alcohol dependence (Table S2 in File S1
summarizes sex-specific pooled RRs) hence the overall pooled
proportions for both sexes combined were used in PAF
calculations. Given that the one RR estimate for amphetamine
dependence was not statistically different (i.e. occurred within
overlapping 95% uncertainty) to the three estimates for cocaine
dependence, we combined them to calculate a pooled RR for all
psychostimulants. This was used to calculate PAFs for both
disorders.
Ceiling values for joint PAFs
Out of 166 psychological autopsy studies reviewed, 43 studies
and 57 estimates covering 20 countries were used to calculate
ceiling value for joint PAFs (Table S3 in File S1 summarizes
included studies). In China, India and Taiwan (group 1), 68.3%
(55.2%–80.0%) of suicide cases was due to mental and substance
use disorders which was lower than in all other countries (group 2),
where 84.5% (78.6%–89.6%) of suicide cases were due to mental
and substance use disorders. These two pooled proportions were
used as the ceiling values for joint PAFs from China, India and
Taiwan (Group 1) and all other countries (Group 2) respectively.
Note that there was considerable heterogeneity between studies.
As we found no statistically significant sex difference, the overall
pooled proportions were used in PAF calculations (Table S4 in File
S1 summarizes sex-specific pooled proportions).
Attributable burden
Mental and substance use disorders were responsible for 22.5
million (14.8–29.8 million) of the 36.2 million (26.5–44.3 million)
DALYs allocated to suicide in 2010, amounting to 62.1% (43.8%–
75.3%) of total suicide DALYs. The proportion of attributable
suicide DALYs in 1990 was almost identical to that in 2010
(62.1% (44.5%–75.4%)). The remainder of this section focuses on
2010 estimates with 1990 estimates summarised in Table S5 in File
S1.
There were twice as many mental and substance use disorders
attributable suicide DALYs for males (14.9 million (9.5–20.1
million)) compared to females (7.6 million (4.4–10.6 million)). For
all disorders, this sex difference was consistent throughout the
lifespan. Attributable suicide DALYs were apparent from those
aged $5 years, with the highest proportion occurring between
those aged 20–30 years (Figure 1).
The proportion of suicide DALYs explained by mental and
substance use disorders was reasonably consistent between regions
and within the range of the ceiling values presented in the previous
section. When considered in terms of absolute DALYs, Asia South
and Asia East had the highest burden attributable to mental and
substance use disorders, given their large population size. In terms
of age-standardized rates, Europe Eastern had the highest burden
(almost 3 times higher than the global mean) and Sub-Saharan
Africa West the lowest (6 times lower than the global mean)
(Figure 2 and Table S5 in File S1 summarize attributable DALYs
by disorder, region, age and sex).
There were also differences in attributable suicide DALYs
across countries (plot 1, figure 3). Attributable DALY rates were
highest in Kazakhstan and lowest in Saudi Arabia, however many
of the country level differences presented in plot 1 were within
overlapping ranges of uncertainty (plot 2, figure 3). Except for
Guyana, Suriname and Zimbabwe, all countries with statistically
higher attributable DALY rates than the global mean were from
Eastern Europe and South Asia. Countries with statistically lower
DALY rates than the global mean included those from South
America, Oceania, Africa and the Middle East and parts of Asia.
Of the suicide DALYs attributable to mental and substance use
disorders, MDD was responsible for the largest proportion (46.1%
(28.0%–60.8%)), followed by alcohol dependence (13.25%
(12.0%–15.0%)), anxiety disorder (7.4% (3.0%–12.7%)), bipolar
disorder (5.4% (1.8%–10.7%)), schizophrenia (4.7% (4.1%–
5.3%)), amphetamine dependence (2.4% (0.9%–4.6%)), opioid
dependence (1.9% (1.1%–2.9%)), cocaine dependence (0.9%
(0.3%–1.8%)) and anorexia nervosa (0.2% (0.02%–0.5%))
(figure 4). MDD explained the most suicide DALYs and anorexia
nervosa the least across all age groups, sex and regions although
most of the age and regional differences between disorders
remained within wide and overlapping confidence intervals (Table
S6 in File S1).
The additional burden attributable to suicide for each mental
and substance use disorder (over and above the DALYs assigned to
them as a direct cause) is also illustrated in figure 4. The inclusion
of attributable suicide burden increased the fatal burden (YLLs)
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due to mental and substance use disorders from 0.5% (0.4%–
0.7%) (assigned to them as a direct cause) to 1.8% (1.4%–2.2%) of
global YLLs and the overall burden (DALYs) of mental and
substance use disorders from 7.4% (6.2%–8.6%) to 8.3% (7.1%–
9.6%) of global DALYs. Out of the 10 leading classes of diseases
included in GBD 2010 [5], mental and substance use disorders
increased from the 5th to the 3rd leading class of disease burden
once the burden attributable to suicide was considered; exceeding
the burden due to neoplasms (7.6% (7.0%–8.2%) of global
DALYs) and neonatal conditions (8.1% (7.3%–9.0%) of global
DALYs) but not cardiovascular and circulatory diseases (11.9%
(11.1%–12.7%) of global DALYs) and diarrhea, LRI, meningitis,
and other common infectious diseases (11.4% (10.4%–12.8%) of
global DALYs). The global DALY ranking of individual disorders
(as presented in GBD 2010’s publication series [5]) also increased
when attributable suicide burden was included (table 2). Although
within overlapping ranges of uncertainty, the ranking for alcohol
dependence increased the most, from the 35th (29th–45th) to the
28th (26th–37th) leading cause of burden.
Discussion
Mental and substance use disorders are associated with an
increased risk of suicide, a finding that is well established in the
literature [19,20,27] but until now, not quantified in terms of a
global comparison of disease burden. DALY rankings in GBD
2010 were based on a classification of mutually exclusive disease
and injury categories [5,10]. Considering the additional burden
due to mental and substance use disorders as a risk factor for
suicide elevated mental and substance use disorders from the fifth
to the third leading disease category of global burden in 2010. Few
mental and substance use disorders are recognized as a primary
cause of death in mortality registrations, and those that are
recognised are often under-represented. The data presented here
provide a more comprehensive insight into the magnitude of the
burden due to these disorders.
Mental and substance use disorders were the cause of two-thirds
of all suicide DALYs reported in GBD 2010. Aside from
emphasising these as a debilitating group of disorders, our findings
highlight the importance of prioritising the prevention, early
detection and effective management of mental and substance use
disorders – particularly MDD – as a key suicide prevention
strategy. Presenting the differences in attributable burden between
regions and countries also provides a beginning for developing
policies or intervention strategies that are applicable at the
national level. Such interventions can be described as ‘selective’, in
the sense that they target subgroups of the population whose
members have yet to manifest suicidal behaviours, but exhibit risk
factors (in this case, mental and substance use disorders) that
predispose them to do so in the future. These can be contrasted
with ‘universal’ interventions, which target whole populations with
the aim of favorably shifting proximal and distal risk (and
protective) factors across the entire population, and ‘indicated
interventions’ which are designed for individuals already exhibit-
ing suicidal behaviours [51].
Typically, countries that have put in place national suicide
prevention strategies have funded a range of universal, selective
and indicated interventions, in recognition of the variety of risk
and protective factors associated with suicide [52]. However our
findings suggest that a relatively greater emphasis on selective
interventions targeting individuals with mental and substance use
disorders may be applicable. By way of example, equipping
general practitioners to detect, diagnose and manage MDD is
likely to have benefits, particularly because many individuals with
MDD will receive care from a general practitioner rather than a
specialist mental health provider. This was one of the few
interventions for which there was good evidence of effectiveness
as a suicide prevention strategy in a recent review by Mann and
colleagues [53]. That said, ensuring that care from general
practitioners is evidence-based requires further consideration,
given findings that rates of minimally adequate treatment for
depression are lower among patients treated solely by general
practitioners or in the general medical care sector, compared to
those treated by specialist mental health providers [54,55].
However universal and indicated interventions have their place,
particularly in low and middle income countries where mental and
substance use disorders were associated with a lesser proportion of
the burden of suicide. In these countries, universal interventions
for example restricting access to means (e.g., pesticides) is worth
pursuing given that they are relatively cheap to implement, can
have a broad community reach and are known to be effective [53].
Although within overlapping bounds of uncertainty, we found
that attributable suicide DALY rates among young people aged
15–19 years were approaching those of the adult age groups.
Table 1. Pooled relative-risk of suicide in those diagnosed with a mental or substance use disorder.
Disorder Number of studies Pooled relative risk (95% UI)
Major depressive disorder 4 19.9 (9.5–41.7)
Anxiety disorder 7 2.7 (1.7–4.3)
Schizophrenia 4 12.6 (11.0–14.5)
Bipolar disorder 4 5.7 (2.6–12.4)
Anorexia nervosa 9 7.6 (2.2–25.6)
Alcohol dependenceb 12 9.8 (9.0–10.7)
Opioid dependence 21 6.9 (4.5–10.5)
Psychostimulant dependence 4 8.2 (3.9–16.9)
Amphetamine dependencea 1 4.5(1.1–9.03)
Cocaine dependencea 3 16.9(6.01–47.2)
Note. 95% UI: 95% uncertainty interval;
aDue to lack of data, simultaneously pooled cocaine and amphetamine relative-risk estimates into an overall estimate for psychostimulants which was applied to both
disorders;
bUsed reported pooled standardised mortality ratios from Wilcox et al [27] for alcohol dependence.
doi:10.1371/journal.pone.0091936.t001
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Figure 1. Suicide DALYs attributable to mental and substance use disorders by age and sex, in 2010.
doi:10.1371/journal.pone.0091936.g001
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Figure 2. Suicide DALYs attributable to mental and substance use disorders by region, in 2010.
doi:10.1371/journal.pone.0091936.g002
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Figure 3. Suicide DALYs (rates per 100,000) attributable to mental and substance use disorders by country, in 2010.
doi:10.1371/journal.pone.0091936.g003
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Although males had higher rates of attributable burden in most
age groups, female rates were higher between the ages of 10 and
19 years. These age-related findings support the importance of
school-based prevention programs which include a focus on
mental health targeted to at-risk adolescents. The sex-difference in
attributable burden also needs to be considered when formulating
prevention strategies for this age group. Although evidence of a
reduction in suicide behaviours has not been demonstrated, there
is evidence for the effectiveness of school-based programs in
reducing the effect of risk factors such as depression [52,56]. A
recent systematic review of interventions targeting adolescents or
young adults at risk of suicide identified individual cognitive
behavioral therapy-based interventions and attachment-based
family therapy as promising interventions, requiring further
investigation [57].
As there was insufficient data to (1) obtain pooled RR estimates
for all countries or regions included in GBD 2010 and (2) clearly
detect differences in RR estimates between all countries/regions,
Figure 4. Suicide DALYs attributable to mental and substance use disorders by disorder, in 2010.
doi:10.1371/journal.pone.0091936.g004
Table 2. Global DALY proportions and rankings before and after the addition of attributable suicide burden, in 2010.
After addition of attributable suicide burden (95% UI)
Disorder Direct DALYs Mean rank Direct plus attributable DALYs Mean rank
As a proportion of total DALYs As a proportion of total DALYs
Major depressive disordera 2.5% (1.9%–3.3%) 11 (7–14) 3.2% (2.5%–4.0%) 8 (4–11)
Anxiety disordera 1.1% (0.8%–1.5%) 26 (19–33) 1.2% (0.9%–1.6%) 25 (17–30)
Alcohol dependencea 0.7% (0.5%–0.9%) 35 (29–45) 0.9% (0.7%–1.1%) 28 (26–37)
Schizophreniaa 0.6% (0.4%–0.7%) 43 (36–57) 0.7% (0.5%–0.9%) 39 (30.5–50)
Bipolar disordera 0.5% (0.3%–0.8%) 46 (35–59) 0.6% (0.4%–0.8%) 44 (31–56)
Mental and substance use disorders
combinedb
7.4% (6.2%–8.6%) 5 (3–6) 8.3% (7.1%–9.6%) 3 (3–6)
Note. DALYs: Disability adjusted life years; 95% UI: 95% uncertainty interval;
aGlobal ranking of direct burden for each disorder was from the official GBD 2010 disease ranking for 2010 [5]. Illicit drug use disorders have not been included here as the
GBD 2010 official disease ranking investigated drug use disorders as group (rather than by specific drug types). Similarly, the ranking for anorexia nervosa was presented in
addition to bulimia nervosa;
bThe global ranking of direct burden of mental and substance use disorders as a group compares the direct burden of the 11 main classes of diseases in GBD 2010 [10].
doi:10.1371/journal.pone.0091936.t002
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the pooled RR estimates used to estimate PAFs were assumed to
be constant across age, sex and country. Instead, the variation in
attributable DALYs across countries was driven by (a function of
both) the prevalence of mental and substance use disorders and the
amount of burden accounted for by suicide in each country. In
addition, given evidence for differences in the underlying causes of
suicide in China, India and Taiwan [45–48], where it has been
well documented that the ease of availability of particularly lethal
means of self-harm such as pesticides may influence patterns of
suicide, we constrained the maximum proportion of suicide
attributable to mental and substance use disorders to a ceiling
value of 68.3%. In spite of this, some Asian countries were
amongst those with the highest rates of attributable suicide burden
due to the high rates of suicide in those countries. This emphasizes
the fact that although there may be other risk factors for suicide,
the prioritisation of mental and substance use disorders in the
prevention of suicide remains a global priority.
The maximum proportion of suicide attributable to mental and
substance use disorders in all other countries was constrained to a
ceiling value of 84.5%. The studies categorized as ‘‘all other
countries’’ were mainly from North America, Western Europe and
Australia and, although we had data for three low to middle
income countries (Colombia, Pakistan and Indonesia), this pooled
proportion might not be appropriate for use in Sub-Saharan
Africa where we found no data. It is possible that these countries
have a different distribution of suicides attributable to mental and
substance use disorders but more cross-national RR data are
required before we can incorporate this in our findings. Islamic
countries, for instance from North Africa/Middle East, were
amongst the countries with the lowest proportion of attributable
burden, despite being allocated the higher ceiling value of 84.5%.
In contrast to the high rates of depression in the Middle East, rates
of suicide were low. The lowest rate of suicide recorded in GBD
2010 was from Saudi Arabia. Stigma around suicide due to
religious beliefs and legislative prohibition (i.e. suicide being
considered as a criminal offence) can lead to fewer cases of suicide
being recorded as a cause of death in countries from the Middle
East. For similar reasons, the degree of psychopathology
underpinning suicide cannot be as clearly assessed in these
countries [58,59]. These issues may have biased our estimates of
attributable burden. The large bounds of uncertainty presented
reflect this to some extent; however, more data are required on the
distribution and aetiology of suicide in these countries to improve
estimates.
Like all population-based analyses, a number of methodological
limitations need to be considered here. The ceiling values for
suicide attributable to mental and substance use disorders were
derived from psychological autopsy studies. As these collect
retrospective data after the individual had died, they are limited
by the accuracy of coroners’ reports and systematic bias from
interviewees [49]. Although the pooled RR estimates used were
derived from more representative population-based prospective
cohort studies, there were only a few estimates available for most
disorders. We applied the same pooled RR across all countries, sex
and age groups for each disorder to reduce errors in estimates as a
result of paucity in the data. It is possible that this masked
differences in the distribution of attributable suicide DALYs. More
representative population cohort studies are now emerging from
low and middle income countries such as India [16]. We hope that
the scrutiny of data presented here will encourage more and better
quality data collection for mental and substance use disorders as
risk factors for suicide. Until then, it is important to consider the
uncertainty around our final estimates in interpreting these
findings.
CRA methodology assumes a causal relationship between the
exposure and outcome [7]. In support for this, the RR estimates
used here showed that mental and substance use disorders were
significantly associated with suicide risk, even when other risk
factors such as socio-economic factors (e.g. adverse marital,
employment and socio-economic status) were considered [20,21].
Another assumption was that the proportion of suicide burden
attributable to mental and substance use disorders was estimated
while holding all other independent risk factors constant. We
estimated the joint effect of all mental and substance use disorders
on suicide while adjusting for comorbidity between these disorders,
the next step would be to explore the joint effect of mental and
substance use disorder with other risk factors of suicide. Finally,
PAF calculations were sensitive to the exposure distribution used.
Here we used DisMod-MR to pool the prevalence of each disorder
based on the raw epidemiological data that were available [10,38].
Although this provided consistent prevalence estimates by country,
region, age, sex, and year, in some cases DisMod-MR was
required to adjust for considerable heterogeneity in the raw data.
This was, to some extent, incorporated in our analyses through the
95% uncertainty intervals around all prevalence estimates
propagated to the final attributable burden estimates.
Conclusions
Mental and substance use disorders were responsible for two
thirds of the suicide burden in 2010, adding a further 22 million
DALYs to their global burden. More consideration needs to be
given to interventions targeted to populations with, or at risk for,
mental and substance use disorders as an effective strategy for
suicide prevention.
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